COVID-19 and Fungal Diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Kyoung-Ho | - |
dc.contributor.author | Lee, Seung-Hoon | - |
dc.date.accessioned | 2022-08-11T03:40:42Z | - |
dc.date.available | 2022-08-11T03:40:42Z | - |
dc.date.created | 2022-08-10 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/142812 | - |
dc.description.abstract | Coronavirus Disease-2019 (COVID-19) can cause secondary bacterial and fungal infections by affecting the expression of pro-inflammatory markers, such as tumor necrosis alpha and certain cytokines, as well as the numbers of CD4 and CD8 cells. In particular, in the head and neck, various fungal species are naturally present, making it the main route of secondary infection. It is difficult to clearly distinguish whether secondary infection is caused by COVID-19 directly or indirectly as a result of the immunocompromised state induced by drugs used to treat the disease. However, the risk of fungal infection is high in patients with severe COVID-19, and lymphopenia is observed in most patients with the disease. Patients with COVID-19 who are immunosuppressed or have other pre-existing comorbidities are at a significantly higher risk of acquiring invasive fungal infections. In order to reduce morbidity and mortality in these patients, early diagnosis is required, and treatment with systemic antifungal drugs or surgical necrotic tissue resection is essential. Therefore, this review aimed to examine the risk of fungal infection in the head and neck of patients with COVID-19 and provide information that could reduce the risk of mortality. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | ORBITAL MUCORMYCOSIS | - |
dc.subject | OUTBREAK | - |
dc.title | COVID-19 and Fungal Diseases | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Kyoung-Ho | - |
dc.contributor.affiliatedAuthor | Lee, Seung-Hoon | - |
dc.identifier.doi | 10.3390/antibiotics11060803 | - |
dc.identifier.scopusid | 2-s2.0-85132551549 | - |
dc.identifier.wosid | 000817604200001 | - |
dc.identifier.bibliographicCitation | ANTIBIOTICS-BASEL, v.11, no.6 | - |
dc.relation.isPartOf | ANTIBIOTICS-BASEL | - |
dc.citation.title | ANTIBIOTICS-BASEL | - |
dc.citation.volume | 11 | - |
dc.citation.number | 6 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ORBITAL MUCORMYCOSIS | - |
dc.subject.keywordPlus | OUTBREAK | - |
dc.subject.keywordAuthor | antifungal therapy | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | fungal infection | - |
dc.subject.keywordAuthor | fungi | - |
dc.subject.keywordAuthor | immunosuppressants | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.